Apellis Pharmaceuticals Inc (APLS)
$47.51
Insights on Apellis Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 8 quarters, 14.38M → 146.37M (in $), with an average increase of 25.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -140.23M → -88.57M (in $), with an average increase of 58.3% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 88.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 239.7%
Performance
- $46.40$48.83$47.51
2.34%
Downside
Day's Volatility :4.98%
Upside
2.7%
- $19.83$94.75$47.51
58.26%
Downside
52 Weeks Volatility :79.07%
Upside
49.86%
Returns
| Period | Apellis Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -24.81% | -0.7% | 0.0% |
6 Months | 4.3% | 6.6% | 0.0% |
1 Year | -41.53% | 3.7% | -1.5% |
3 Years | 4.46% | 14.0% | -21.8% |
Highlights
Market Capitalization | 6.2B |
Book Value | $1.63 |
Earnings Per Share (EPS) | -4.45 |
Wall Street Target Price | 82.8 |
Profit Margin | -133.29% |
Operating Margin TTM | -57.74% |
Return On Assets TTM | -41.73% |
Return On Equity TTM | -290.14% |
Revenue TTM | 396.6M |
Revenue Per Share TTM | 3.34 |
Quarterly Revenue Growth YOY | 545.9% |
Gross Profit TTM | 69.8M |
EBITDA | -515.3M |
Diluted Eps TTM | -4.45 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.23 |
EPS Estimate Next Year | 1.2 |
EPS Estimate Current Quarter | -0.69 |
EPS Estimate Next Quarter | -0.52 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 74.28%
Technicals Summary
Sell
Neutral
Buy
Apellis Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Apellis Pharmaceuticals Inc | -14.63% | 4.3% | -41.53% | 4.46% | 154.4% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | NA | NA | NA | -1.23 | -2.9 | -0.42 | NA | 1.63 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | Buy | $6.2B | 154.4% | NA | -133.29% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Wellington Management Company LLP
13.76%EcoR1 Capital, LLC
9.35%venBio Select Advisor LLC
9.29%Vanguard Group Inc
7.99%T. Rowe Price Investment Management,Inc.
5.27%BlackRock Inc
4.50%
Corporate Announcements
Apellis Pharmaceuticals Inc Earnings
Apellis Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Organization | Apellis Pharmaceuticals Inc |
Employees | 702 |
CEO | Dr. Cedric Francois M.D., Ph.D. |
Industry | Distribution Services |
Discover More
Vanguard Ultra Short Bond Et
$47.51
-1.08%
Surgery Partners Inc
$47.51
-1.08%
Sl Green Realty Corp.
$47.51
-1.08%
Goldman Sachs Activebeta Int
$47.51
-1.08%
Allegro Microsystems, Inc.
$47.51
-1.08%
Cleanspark Inc
$47.51
-1.08%
Chart Industries Inc.
$47.51
-1.08%
Agree Realty Corp
$47.51
-1.08%
Joby Aviation Inc
$47.51
-1.08%